Heart Failure with Preserved Ejection Fraction in Cancer Patients and Survivors. A Scientific Statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology
Recommendations
As issued by the authors
Include heart failure with preserved ejection fraction (HFpEF) in the cardiotoxicities identified during or after anticancer treatments
Consider HFpEF from cancer diagnosis throughout treatment and survivorship
Original publication
Heart Failure with Preserved Ejection Fraction in Cancer Patients and Survivors. A Scientific Statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology. Eur J Heart Fail. Published 12 September 2025. doi:10.
Summarised from the published abstract; every number is checked against it